Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 18/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.75 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.75 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.75 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.75 |
| ▸ | MLNR | O43193 | 1/20 | 0.75 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.75 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | PGR | P06401 | 1/20 | 0.75 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.75 |
| ▸ | HTR1A | P08908 | 1/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3716311 | 1.00 | CYP3A4 (0.75) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL794553 | 1.00 | CYP3A4 (0.75) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL8269408 | 0.97 | CYP3A4 (0.77) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL2913540 | 0.97 | CYP3A4 (0.77) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL13748639 | 0.89 | CYP3A4 (0.69) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL13749205 | 0.89 | CYP3A4 (0.69) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL3039096 | 0.89 | CYP3A4 (0.71) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL2916535 | 0.88 | CYP3A4 (0.67) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL7091785 | 0.87 | CYP3A4 (0.81) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL2736324 | 0.87 | CYP3A4 (0.77) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4161951-A1 | METHODS FOR DETECTING AND TREATING COVID PATIENTS REQUIRING INTENSIVE CARE | Institut Gustave-Roussy (FR) | 2023-04-12 | — | — | EP | disclosed |
| US-20100099885-A1 | PROCESS FOR THE PREPARATION OF FORM I AND FORM II OF RITONAVIR | RANBAXY LABORATORIES LIMITED (IN) | 2010-04-22 | — | — | US | disclosed |
| US-7427600-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-7060708-B2 | Active agent delivery systems and methods for protecting and administering active agents | NEW RIVER PHARMACEUTICALS INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-6911214-B2 | Containing lopinavir or its mixtures, comprising a sweetener, two or more flavoring agents menthol, peppermint, vanilla, cotton candy flavors, and flavor modifier such as sodium citrate, sodium chloride and citric acid | ABBOTT LABORATORIES (US) | 2005-06-28 | — | — | US | disclosed |
| US-20020198160-A1 | Compositions and methods for enhancing the bioavailability of pharmaceutical agents | ABBOTT LABORATORIES | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099885-A1 | PROCESS FOR THE PREPARATION OF FORM I AND FORM II OF RITONAVIR | CYP2F1, CYP3A5, CYP3A4 | CYP3A4 3/4885CYP2D6 41/4885CYP2C9 18/4885 |
| US-20020198160-A1 | Compositions and methods for enhancing the bioavailability of pharmaceutical agents | ABCG2, ABCB1, CYP3A5 | CYP3A4 12/4885CYP2D6 28/4885CYP2C9 44/4885 |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | VIP, BST2, FCGR3B | CYP3A4 2045/4885CYP2D6 1285/4885CYP2C9 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.